Angela Effinger

Predicting budesonide performance in healthy subjects and patients with Crohn's disease using biorelevant in vitro dissolution testing and PBPK modeling

Angela Effinger, Caitríona M. O’Driscoll, Mark McAllister et al. · European Journal of Pharmaceutical Sciences · 2020 · 27 citations

Budesonide Performance, Pharmacokinetic Modeling, Healthy Subjects +6

Gastrointestinal diseases and their impact on drug solubility: Crohn's disease

Angela Effinger, Caitríona M. O’Driscoll, Mark McAllister et al. · European Journal of Pharmaceutical Sciences · 2020 · 17 citations · Full text

Functional Gastrointestinal Disorder, Gastrointestinal Pharmacology, Medicine +6

Investigating the Impact of Crohn’s Disease on the Bioaccessibility of a Lipid-Based Formulation with an In Vitro Dynamic Gastrointestinal Model

Angela Effinger, Mark McAllister, Irena Tomaszewska et al. · Molecular Pharmaceutics · 2021 · 15 citations

Lipid-based Formulation, Biochemistry, Fatty Acids +15

Gastrointestinal diseases and their impact on drug solubility: Celiac disease

Angela Effinger, Caitríona M. O’Driscoll, Mark McAllister et al. · European Journal of Pharmaceutical Sciences · 2020 · 11 citations · Full text

Gastrointestinal diseases and their impact on drug solubility: Ulcerative Colitis

Angela Effinger, Caitríona M. O’Driscoll, Mark McAllister et al. · European Journal of Pharmaceutical Sciences · 2020 · 10 citations · Full text